Obesity and osteoarthritis (OA) co-exist in an increasing part of the population. The two diseases intertwine in several ways. The evolution in the population shows a tendency towards deterioration of both by increasing general age and weight. The two diseases share pathogenetic features and the development of one disease increases the risk of the other and may be the onset of a vicious circle. There is a link between treatments of these two diseases as well. There is now solid (gold) evidence that by treating effectively the obesity of patients with co-occurring OA, the functional status is dramatically ameliorated; the short-term results are equal to that of a joint replacement. The long-term efficacy of a weight loss remains to be shown. OA is definitely one of many diseases in which obesity must be taken seriously into account when planning a correct treatment of patients. This trial has two phases, the first (16 weeks) consisting of a dietary intervention with low-energy diet and the second (52 weeks) a randomized, three group (each n\>50 patients) controlled study of maintenance of weight loss by either continuing dietary instruction, exercise, or a control group. The hypothesis is that maintenance of an initially induced weight loss is dependent on attention rather than any specific therapy.
Any patient with osteoarthritis (OA)of the knee and concomitant obesity will be considered for participation. Eligible for this study will be patients with radiographical knee OA. Exclusion criteria are recent or planned knee operations, alloplasties in both knees, ongoing or planned alternative interventions against obesity.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
192
Weekly instruction by dieticians
Supervised exercise in groups
The Parker Institute, Frederiksberg Hospital
Frederiksberg, Frederiksberg, Denmark
Pain
Time frame: 16 weeks, 68 weeks
OMERACT-OARSI response criterion
Time frame: 16 weeks, 68 weeks
Weight change
Time frame: 8 weeks, 16 weeks, 68 weeks
Gait analysis
Time frame: 16 weeks, 68 weeks
MRI
Time frame: 16 weeks, 68 weeks
Ultrasound
Time frame: 16 weeks, 68 weeks
Collagen markers
Time frame: 16 weeks, 68 weeks
Metabolic syndrome
Time frame: 8 weeks, 16 weeks, 68 weeks
KOOS
Time frame: 16 weeks, 68 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.